Prelude Therapeutics
Price & Volume
Stats
See more52W Range | $0.75-$5.69 |
Market Cap | $366.3M |
Shares Short | 3M |
Financials
See moreRevenue (12 Mos) | $16.7M |
Revenue Growth (YoY) | 41% |
Gross Profit (12 Mos) | $16.7M |
Diluted EPS | -$0.91 |
News
See moreYahoo Finance • 5 months ago
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Yahoo Finance • 8 months ago
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
About
CEO | Dr. Krishna Vaddi D.V.M., Ph.D. |
CFO | Mr. Bryant David Lim J.D. |
Address | 175 Innovation Boulevard, Wilmington, DE, United States, 19805 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 79 |